NEW YORK--(BUSINESS WIRE)--PharmaVOICE has named Asaf Evenhaim, the CEO and co-founder of Crossix, as one of its PharmaVOICE 100 for the second time. He first received this honor in 2012.
Now in its fifteenth year, the PharmaVOICE 100 is an annual list of inspiring individuals recognized for their positive contributions to the life sciences industry. Evenhaim was recognized for his contributions in developing cutting-edge, privacy-safe solutions that help marketers have true visibility into their marketing performance for both direct-to-consumer and healthcare professional campaigns.
Evenhaim joins 99 other honorees, who represent a broad cross-section of industry sectors, including pharmaceutical, biopharmaceutical, biotechnology, contract research, clinical trial, research and development, patient education, patient recruitment, advertising, marketing, technology, training, mentoring, and many others.
“Two-time PharmaVOICE 100 honoree Asaf inspires his team by continuing to embody the company’s core values: breaking down barriers allowing everyone to innovate,” says Taren Grom, editor, PharmaVOICE.
Evenhaim and his fellow honorees will be formally recognized at a celebratory event on Thursday, September 12, in New York City at The Lighthouse at Chelsea Piers.
About Crossix Solutions
Crossix partners with top health brands to maximize media and marketing effectiveness through robust data analytics. Fueled by our privacy-by-design, patented Crossix SafeMine™ technology, Crossix connects the industry’s most comprehensive set of health and non-health data, covering more than 300 million lives in the US. Crossix DIFA™, our best-in-class, cloud-based platform, allows real-time measurement and optimization of complex, cross-channel media campaigns aimed at patients and healthcare professionals.
Our customers include all the top 25 pharma companies, leading health systems, pharmacies and other wellness brands. Founded in 2004, Crossix is headquartered in New York City with offices in Israel and Belarus. For more information, visit www.crossix.com.
PharmaVOICE is expressly written and designed to deliver the views, opinions, and insights of executives who are shaping the direction of the dynamic life-sciences industry. PharmaVOICE reaches more than 46,000 BPA qualified subscribers and is distributed to 60,000 industry executives with the digital edition. Our circulation includes executives from pharmaceutical manufacturing, biotechnology, drug discovery, research & development, contract research, drug delivery, and device/diagnostic companies. The publication also targets decision makers at healthcare advertising, marketing, medical education, public relations, information technology, contract sales, traditional and nontraditional media, and other service support companies and organizations. The publication also reaches more than 60,000 users with its digital edition, which contains original exclusive bonus content.